The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event
Paola Zaratin(Associazione Italiana Sclerosi Multipla), Patrick Vermersch(Université de Lille), Guy Peryer(Multiple Sclerosis Society), Abdülkadir Tunç(Sakarya University), Jeremy Hobart(Peninsula College of Medicine and Dentistry), Loïc Carment, Peer Baneke(Multiple Sclerosis International Federation), Giampaolo Brichetto(Associazione Italiana Sclerosi Multipla), Sara Samadzadeh(University of Southern Denmark), Anne Helme(Multiple Sclerosis International Federation), Usman A. Khan(KU Leuven), Valerie J. Block(University of California, San Francisco), Patricia Moghames, Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Angela White(National Multiple Sclerosis Society), Gary Cutter(Alabama Department of Public Health), Timothy Coetzee(National Multiple Sclerosis Society), Letizia Leocani(Vita-Salute San Raffaele University), Gıancarlo Comı(Vita-Salute San Raffaele University), Robert McBurney(Accelerated Cure Project for Multiple Sclerosis), Vito A. G. Ricigliano(Inserm), Jan Hillert, Luca Capezzuto(Roche (Switzerland)), Liesbet M. Peeters(Hasselt University), Maria Pia Sormani(University of Genoa), Jonadab dos Santos Silva(Universidade Federal Fluminense), Mario Alberto Battaglia(University of Siena), Meral Seferoğlu(University of Health Science), Helga Weiland, Susanna van Tonder, Hans-Peter Hartung(The University of Sydney), Paolo Angelo Cortesi(University of Milano-Bicocca), Rod Middleton(Swansea University), Kaisa Immonen(European Medicines Agency), Paul Kamudoni(Merck KGaA, Darmstadt (Germany))
Cited by 24
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k